Andrew Young
Chief Scientific & Medical Officer I2O Therapeutics
Andrew Young, a 36-year pioneer in biopharmaceuticals, was most recently Chief Scientific Officer at Intarcia Therapeutics Inc. Other biopharmaceutic roles include head of Enteroendocrine Biology at GlaxoSmithKline, NC, and founding physiologist at Amylin Pharmaceuticals Inc in San Diego (VP, Research and Sr Research Fellow) where he led physiologic characterization of the new hormone, amylin. An analog, pramlintide (SYMLIN), was a first-in-class treatment for insulin-requiring diabetes. He led acquisition and initial development of exenatide (BYETTA and BYDUREON) the first GLP1 agonist for treatment of type 2 diabetes. He co-discovered the use of PYY for metabolic diseases. He has contributed to 6 New Drug Applications. He has co-founded 2 biotech companies. Satiogen Pharmaceuticals Inc (San Diego) based upon bile acid based signaling via drugs and devices (part divested as Lumena, sold to Shire). Satiogen and Lumena IP led to Mirum and the first approved treatment for Alagilles and other forms of cholestatic jaundice, also approved in EU. The metabolic aspects of bile salt were spun into Bilarm Health after Mirum?s acquisition of Satiogen. He co-founded Phoundry Pharmaceuticals Inc, spun out of GlaxoSmithKline, dedicated to discovery of highly potent peptides suitable for convenient delivery systems. Andrew was CSO until Phoundry?s acquisition by Intarcia Therapeutics, Inc. in 2015. Entrepreneur-in-Residence at New Rhein Healthcare Investors. Consultant for Aktis Oncology, i2O Biosciences, Glycend and several (undisclosed) others.
Seminars
This intensive workshop will delve into the advanced quantitative strategies necessary for navigating the complexity and high investment of developing multi-target and combination GLP-1 therapeutics. Leveraging deep experience from both large pharma and pioneering biotech, the session will focus on transforming traditional trial execution into a continuous, model-informed decision engine to minimize risk, maximize capital efficiency, and accelerate time to market for novel cardiometabolic solutions.
This workshop will gather experts to discuss:
- Integrating model-informed drug development (MIDD) strategies to reduce the required size and duration of costly Phase 2 and 3 combination trials, ensuring dose selection is robust and scientifically grounded
- Applying advanced pharmacometric (PMX) and PBPK modeling to predict synergistic or antagonistic effects of novel GLP-1 combinations (including oral formulations) and optimize dosing schedules before committing to large-scale clinical studies
- Designing efficient, adaptive clinical protocols that incorporate Bayesian and other quantitative methods to dynamically adjust dose levels, target populations, and hypothesis testing in real-time
- Quantifying the translational power of combination therapies by linking pre-clinical data (neurobiology, whole animal response) directly to human efficacy and safety endpoints to justify increased development spend
- Establishing effective cross-functional decision-making gates between Quantitative Pharmacology, Clinical Development, and Research to accelerate development timelines for therapeutics targeting obesity and MASH/NASH
